Features Screener Stocks Charts
Sign In Sign Up

Ipca Laboratories Ltd. Cash Flow Statement

NSE:IPCALAB | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

1.17x

IPCALAB's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.

Free Cash Flow

₹5.46B

IPCALAB's free cash flow was ₹5.46B in FY 2025, up 2.2% from FY 2024.

Dividend Coverage

5.4x

IPCALAB's free cash flow covered dividends 5.4x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

58.7%

Capital expenditure was 58.7% of operating cash flow in FY 2025 for IPCALAB, a moderate level of reinvestment.

2-year IPCALAB cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 8.43B 11.31B
Cash flow Operating Activities 9.45B 13.21B
Investments in PPE -4.11B -7.76B
Cash flow Investing Activities -12.92B -8.70B
Dividend Paid -507.40M -1.01B
Cash flow Financing Activities -5.53B -2.83B
Cash at beginning of period 15.79B 7.56B
Cash at end of period 7.56B 9.25B
Free Cash Flow 5.34B 5.46B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025